Loading clinical trials...
Loading clinical trials...
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Angiotensin II Type 1 Receptor Blockers (ARBs) on Outcomes of Coronavirus Infection?
Conditions
Interventions
ARBs and/or ACE inhibitors
Usual Care
Locations
15
Canada
University of Calgary - Foothills
Calgary, Alberta, Canada
Stollery Children's Hospital
Edmonton, Alberta, Canada
University of Alberta
Edmonton, Alberta, Canada
Surrey Memorial Hospital
Surrey, British Columbia, Canada
St Pauls Hospital
Vancouver, British Columbia, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
Start Date
March 17, 2020
Primary Completion Date
June 30, 2021
Completion Date
June 30, 2022
Last Updated
August 12, 2020
NCT07221162
NCT06082518
NCT06631287
NCT06679140
NCT06417762
NCT03830320
Lead Sponsor
University of British Columbia
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions